Benfotiamine Protects against Peritoneal and Kidney Damage in Peritoneal Dialysis
| Autor: | Martin Zeier, Antonysunil Adaikalakoteswari, Lars P. Kihm, Vedat Schwenger, Paul J. Thornalley, Peter P. Nawroth, Sandra Müller-Krebs, Marie-Luise Gross, Gregory Ehrlich, Julia Klein, Laura Mertes, Hans-Peter Hammes |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Glycation End Products
Advanced Male Vascular Endothelial Growth Factor A Nephrology medicine.medical_specialty medicine.medical_treatment Receptor for Advanced Glycation End Products Kidney Peritoneal dialysis Rats Sprague-Dawley Peritoneum Internal medicine medicine Albuminuria Animals Thiamine Receptors Immunologic Peritoneal Fibrosis Uremia business.industry General Medicine Fibrosis Rats B vitamins Basic Research medicine.anatomical_structure Endocrinology Benfotiamine Transketolase activity Transketolase Reactive Oxygen Species business Peritoneal Dialysis medicine.drug |
| Zdroj: | Journal of the American Society of Nephrology. 22:914-926 |
| ISSN: | 1046-6673 |
| DOI: | 10.1681/asn.2010070750 |
| Popis: | Residual renal function and the integrity of the peritoneal membrane contribute to morbidity and mortality among patients treated with peritoneal dialysis. Glucose and its degradation products likely contribute to the deterioration of the remnant kidney and damage to the peritoneum. Benfotiamine decreases glucose-induced tissue damage, suggesting the potential for benefit in peritoneal dialysis. Here, in a model of peritoneal dialysis in uremic rats, treatment with benfotiamine decreased peritoneal fibrosis, markers of inflammation, and neovascularization, resulting in improved characteristics of peritoneal transport. Furthermore, rats treated with benfotiamine exhibited lower expression of advanced glycation endproducts and their receptor in the peritoneum and the kidney, reduced glomerular and tubulointerstitial damage, and less albuminuria. Increased activity of transketolase in tissue and blood contributed to the protective effects of benfotiamine. In primary human peritoneal mesothelial cells, the addition of benfotiamine led to enhanced transketolase activity and decreased expression of advanced glycation endproducts and their receptor. Taken together, these data suggest that benfotiamine protects the peritoneal membrane and remnant kidney in a rat model of peritoneal dialysis and uremia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|